INSM Insmed Inc.

20.89
-0.57  -3%
Previous Close 21.46
Open 21.23
Price To Book 6.14
Market Cap 1,865,943,550
Shares 89,343,718
Volume 905,334
Short Ratio
Av. Daily Volume 875,861
Stock charts supplied by TradingView

NewsSee all news

  1. Insmed to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BRIDGEWATER, N.J., Jan. 9, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  2. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Jan. 3, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  3. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Dec. 3, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  4. Insmed to Present at Two December Conferences

    BRIDGEWATER, N.J., Nov. 26, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  5. Insmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer

    BRIDGEWATER, N.J., Nov. 14, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due 1Q 2020.
INS1007
Bronchiectasis
Phase 2 ready.
INS1009
Pulmonary arterial hypertension (PAH)
Phase 3 Euro data released 1 July 2013. Met endpoint but slighly inferior data to competition
ARIKAYCE
Cystic fibrosis
FDA Approval announced September 28, 2018.
ARIKAYCE
Nontuberculous mycobacterial (NTM) lung disease

Latest News

  1. Insmed to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BRIDGEWATER, N.J., Jan. 9, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  2. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Jan. 3, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  3. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Dec. 3, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  4. Insmed to Present at Two December Conferences

    BRIDGEWATER, N.J., Nov. 26, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  5. Insmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer

    BRIDGEWATER, N.J., Nov. 14, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  6. Insmed to Present at Two November Conferences

    BRIDGEWATER, N.J., Nov. 5, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  7. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  8. Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update

    BRIDGEWATER, N.J., Oct. 30, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported

  9. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Oct. 7, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  10. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Sept. 5, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  11. Insmed to Present at Two September Conferences

    BRIDGEWATER, N.J., Sept. 3, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced